Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
Belgium
/
Pharmaceuticals & Biotech
Create a narrative
UCB Community
ENXTBR:UCB Community
3
Narratives
written by author
0
Comments
on narratives written by author
26
Fair Values set
on narratives written by author
Create a narrative
UCB
Popular
Undervalued
Overvalued
Community Investing Ideas
UCB
AN
AnalystConsensusTarget
Consensus Narrative from 18 Analysts
BIMZELX's Successful Launch Will Expand Future Market Opportunities In Dermatology And Rheumatology
Key Takeaways UCB's new product launches and high R&D success rate are driving anticipated revenue and margin growth across global markets. Expansion in therapeutic areas like Alzheimer's and dermatology aims to meet unmet needs and boost profitability.
View narrative
€208.43
FV
17.2% undervalued
intrinsic discount
11.89%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
18
users have followed this narrative
7 days ago
author updated this narrative
UCB
AN
AnalystHighTarget
Consensus Narrative from 18 Analysts
Digital Health And Biologics Will Serve Aging Populations
Key Takeaways Blockbuster biologics launches and strong pipeline performance position revenue and margin growth to outpace expectations, benefiting from rapid geographic expansion and operational leverage. Strategic reinvestment, portfolio optimization, and advanced digital health integration bolster flexibility, innovation, and sustained profitability above consensus forecasts.
View narrative
€250.00
FV
31.0% undervalued
intrinsic discount
17.72%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
9 days ago
author updated this narrative
UCB
AN
AnalystLowTarget
Consensus Narrative from 18 Analysts
Global Regulatory Scrutiny And Pricing Pressures Will Erode Margins
Key Takeaways Erosion of pricing power and reimbursement constraints are compressing margins and limiting the ability to convert prescription growth into sustainable revenue gains. Pipeline and legacy products face revenue risks from generic competition, innovation disruption, and rising R&D costs challenging long-term business model viability.
View narrative
€154.73
FV
11.5% overvalued
intrinsic discount
6.57%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 2 months ago
author updated this narrative
Your Valuation for
UCB
UCB
UCB
Your Fair Value
€
Current Price
€172.55
16.7% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
0
10b
2015
2018
2021
2024
2025
2027
2030
Revenue €9.9b
Earnings €1.7b
Advanced
Set Fair Value